Clinical Trials Sponsored by Acarix

Total 327 results

Acarix

Completed

Identification of Heart Failure Patients by Seismocardiography (SCG-HF)

Heart Failure

Denmark
Acarix

Completed

Data Acquisition for Optimization of Coronary Artery Disease (CAD) Algorithm

Coronary Artery Disease

Denmark
Acarix
Rigshospitalet, Denmark

Completed

Data Aquisition for Optimization of Coronary Artery Disease Algorithm

Coronary Artery Disease

Denmark
Bispebjerg Hospital
Larix A/S; Region Hovedstadens Apotek; Acarix; Kai Hansen Foundation; Kai Houmann...

Completed

Cost-effectiveness and Safety of the CADScorSystem in Patients With Symptoms Suggestive of Stable Coronary Artery Disease. (FILTER-SCAD)

Angina, Stable

Denmark, Sweden
Acarix
Rigshospitalet, Denmark; Steno Diabetes Center Copenhagen

Completed

Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients (CAD-risk)

Coronary Arteriosclerosis

Denmark
Andarix Pharmaceuticals

Recruiting

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Small Cell | Neoplasm Recurrence, Local

United States
Acadia University

Unknown

Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression

Depression | Anxiety

Canada
ACADIA Pharmaceuticals Inc.

Recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Recruiting

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Irritability Associated With Autism Spectrum Disorder

United States, Spain, France, Hungary, Poland, Italy
ACADIA Pharmaceuticals Inc.

Completed

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Completed

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Serbia, United States, Poland, Georgia, Russian Federation, Bulgaria, Colombia, Czechia, Mexico, Romania, South Africa, Ukraine
Aclaris Therapeutics, Inc.

Completed

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Atopic Dermatitis

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Atopic Dermatitis

United States
ACADIA Pharmaceuticals Inc.

Completed

Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Acute Postoperative Pain | Bunionectomy

United States
ACADIA Pharmaceuticals Inc.

Terminated

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Osteoarthritis Pain

United States
Acacia Pharma Ltd

Completed

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

Renal Disease, End Stage

United States
Aclaris Therapeutics, Inc.

Completed

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Androgenetic Alopecia

United States
Aclaris Therapeutics, Inc.

Completed

Study of A-101 for the Treatment of Seborrheic Keratosis

Seborrheic Keratosis

United States
Acacia Pharma Ltd

Completed

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

CINV

Denmark
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Aclaris Therapeutics, Inc.

Terminated

A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Alopecia Areata

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Dermatosis Papulosa Nigra

United States
Aclaris Therapeutics, Inc.

Completed

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Acacia Pharma Ltd

Completed

European Phase III Study of APD421 in PONV

PONV

France, Germany
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

Common Wart

United States
Acacia Pharma Ltd

Completed

Phase II Dose-ranging Study of APD421 in PONV

Postoperative Nausea and Vomiting

United States, Germany, France
Aclaris Therapeutics, Inc.

Completed

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

An Open-Label Safety Study of A-101 Solution

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis (SK)

Seborrheic Keratosis

United States
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis

United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

Spain, United States, Belgium, Austria, Serbia, Poland, Portugal, Italy, Sweden
ACADIA Pharmaceuticals Inc.

Approved for marketing

Expanded Access of Pimavanserin for Patients With PD Psychosis

Parkinson's Disease Psychosis
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

United States, Canada
Acacia Pharma Ltd

Completed

Pilot Study of APD209 in Cancer Cachexia

Cancer-related Cachexia

United Kingdom
ACADIA Pharmaceuticals Inc.

Not yet recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Alzheimer's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Recruiting

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Schizophrenia

Lithuania, Canada, Ukraine, Argentina, Bulgaria, Croatia, Czechia, Hungary, Italy, Poland, Russian Federation, Serbia, Spain, United States
Aclaris Therapeutics, Inc.

Completed

ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA

Rheumatoid Arthritis

United States, Bulgaria, Czechia, Poland
ACADIA Pharmaceuticals Inc.

Completed

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome (DAFFODIL™)

Rett Syndrome

United States
Amarin Pharma Inc.

Completed

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (MARINE)

Hypertriglyceridemia

United States, Netherlands, Russian Federation, Ukraine, Denmark, Finland, Germany, India, Italy, Mexico, South Africa
Amarin Pharma Inc.

Completed

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (ANCHOR)

Hypertriglyceridemia

United States
Amarin Pharma Inc.

Completed

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (REDUCE-IT)

Cardiovascular Diseases

United States, Australia, Canada, India, Netherlands, New Zealand, Poland, Romania, Russian Federation, South Africa, Ukraine
ACADIA Pharmaceuticals Inc.

Terminated

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Ukraine, United Kingdom, Slovakia, South Africa
Aclaris Therapeutics, Inc.

Completed

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
ACADIA Pharmaceuticals Inc.

Completed

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

Parkinson's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Completed

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

Treatment of Depression in Adults With Parkinson's Disease (PD)

United States
Aclaris Therapeutics, Inc.

Completed

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

Alopecia Totalis (AT) | Alopecia Universalis (AU)

United States
ACADIA Pharmaceuticals Inc.

Completed

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

Schizophrenia

United States, Russian Federation, Hungary, Bulgaria, Serbia, Ukraine, Lithuania, Canada, Czechia, Poland
Aclaris Therapeutics, Inc.

Completed

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (SK-FAN)

Seborrheic Keratosis

United States

Clinical Trials Sponsored by Acarix

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations